1042 related articles for article (PubMed ID: 18615251)
1. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
2. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
4. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
5. Innovative strategies for early clinical R&D.
Butz RF; Morelli G
IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
[TBL] [Abstract][Full Text] [Related]
6. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
[TBL] [Abstract][Full Text] [Related]
7. Leveraging exploratory investigational new drug studies to accelerate drug development.
Jacobson-Kram D; Mills G
Clin Cancer Res; 2008 Jun; 14(12):3670-4. PubMed ID: 18559581
[TBL] [Abstract][Full Text] [Related]
8. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
[TBL] [Abstract][Full Text] [Related]
9. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
10. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
LoRusso PM; Boerner SA; Seymour L
Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
[TBL] [Abstract][Full Text] [Related]
11. The ethics of phase 0 oncology trials.
Abdoler E; Taylor H; Wendler D
Clin Cancer Res; 2008 Jun; 14(12):3692-7. PubMed ID: 18559585
[TBL] [Abstract][Full Text] [Related]
12. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
13. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
Senderowicz AM
Clin Cancer Res; 2010 Mar; 16(6):1719-25. PubMed ID: 20215544
[TBL] [Abstract][Full Text] [Related]
14. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
15. Can single-patient investigational new drug studies hurry slow trains to the fast track?
Chenoweth D
Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
[TBL] [Abstract][Full Text] [Related]
16. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
[TBL] [Abstract][Full Text] [Related]
18. End points in cancer clinical trials and the drug approval process.
Schilsky RL
Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
[TBL] [Abstract][Full Text] [Related]
19. Risks and benefits associated with novel phase 1 oncology trial designs.
Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
[TBL] [Abstract][Full Text] [Related]
20. Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Theoret MR; Pai-Scherf LH; Chuk MK; Prowell TM; Balasubramaniam S; Kim T; Kim G; Kluetz PG; Keegan P; Pazdur R
Clin Cancer Res; 2015 Oct; 21(20):4545-51. PubMed ID: 26473190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
